DelveInsight’s, “T-Cell Lymphoma – Pipeline Insight, 2024,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The T-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
T-Cell Lymphoma Overview
T-cell lymphomas are a rare and uncommon subtype of non-Hodgkin lymphomas that can arise in lymphoid tissues such as lymph nodes and the spleen, or outside these tissues in areas like the gastrointestinal tract, liver, nasal cavity, and skin. Compared to B-cell lymphomas, T-cell lymphomas generally have a poorer prognosis. Most T-cell lymphomas originate from mature T cells and typically affect adults, with a peak incidence in individuals in their mid-60s. They are more prevalent in men than in women. In some cases, T-cell lymphomas can develop from immature T cells, a condition known as T-cell lymphoblastic lymphoma, which tends to affect children and young adults.
There are numerous types of T-cell lymphoma, including T-lymphoblastic lymphoma/leukemia, Peripheral T-cell lymphomas, Cutaneous T-cell lymphomas, Adult T-cell leukemia/lymphoma, Anaplastic Large Cell Lymphoma, and Angioimmunoblastic T-Cell Lymphoma, among others. With approximately 20 different types of T-cell lymphoma that can originate in various parts of the body, symptoms can vary widely among individuals. The symptoms of T-cell lymphomas depend on the specific type of lymphoma and its location in the body. The most common symptom is swollen lymph nodes, while skin rashes or other skin-related symptoms are more frequent in certain types of T-cell lymphomas. Lymphoma that originates in the lymph nodes is termed ‘nodal lymphoma,’ but many T-cell lymphomas develop outside the lymph nodes or in organs such as the liver, bone marrow, gut, or skin. Some common symptoms of lymphoma include fatigue, loss of appetite, bone or joint pain, muscle weakness, and liver enlargement.
Due to their rarity, T-cell lymphomas can be challenging to diagnose. Diagnosis typically involves a biopsy and a PET/CT scan. In some cases, particularly in children or individuals with lymphoma in the central nervous system, an MRI scan may also be used.
The treatment for T-cell lymphoma depends on the subtype of lymphoma, its aggressiveness, the symptoms, and personal preferences. Common treatment options include chemotherapy, monoclonal antibodies (Mabs) such as cytokine inhibitors and conjugated Mabs, targeted therapies, and radiotherapy.
T-Cell Lymphoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of T-Cell Lymphoma and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the T-Cell Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
T-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Topical
-
Intravenous
Molecule Type
Products have been categorized under various Molecule types, such as
-
Bispecific antibody
-
CAR-T cell therapies
-
Gene therapies
-
Cell therapies
-
Monoclonal antibodies
-
Peptides
-
Recombinant proteins
-
Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
-
HSP90 heat-shock protein inhibitors
-
Apoptosis stimulants; Cell division inhibitors
-
Antibody-dependent cell cytotoxicity
-
Cell replacements; Immunologic cytotoxicity
-
Enhancer of zeste homolog 1 protein inhibitors; Enhancer of zeste homolog 2 protein inhibitors
-
KIR3DL2 receptor antagonists
-
Gene transference
-
Immunologic cytotoxicity; T lymphocyte replacements
-
Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
Learn How the Ongoing Clinical & Commercial Activities will Affect the T-Cell Lymphoma Therapeutic Segment
T-Cell Lymphoma Therapeutics Landscape
T-cell lymphomas are rare and can be challenging to diagnose. The diagnosis of T-cell lymphoma typically relies on a biopsy, where a sample of affected tissue, such as a swollen lymph node, is removed and examined by a specialized lymphoma pathologist.
The most commonly used combination chemotherapy regimen is CHOP, which includes cyclophosphamide, doxorubicin (or hydroxydaunorubicin), vincristine (also known as Oncovin), and prednisolone (a steroid). For younger individuals with T-cell lymphoma who have responded well to initial chemotherapy, an autologous stem cell transplant is often recommended.
Several major pharmaceutical and biotechnology companies are developing therapies for T-Cell Lymphoma to enhance the treatment landscape. Currently, Genor Biopharma is at the forefront of the therapeutics market with its T-Cell Lymphoma drug candidates in the most advanced stages of clinical development.
Leading Companies in the T-Cell Lymphoma Therapeutics Market Include:
Affimed Therapeutics, Aileron Therapeutics, Akeso Biopharma, Applied Therapeutics, Astex Therapeutics, Autolus, AVM Biotechnology, Ayala Pharmaceuticals, BeiGene, Bioniz, Bristol Myers Squibb, Celgene, Celleron Therapeutics, CerRx, Chia Tai Tianqing Pharmaceutical Group, CRISPR Therapeutics, CStone Pharmaceutical, Daiichi Sankyo, Dizal Pharmaceutical, Eli Lilly and Company, Eutilex, Galderma, Genor Biopharma, Hoffman-La-Roche, ImmuneOncia Therapeutics, Innate Pharma, Janssen Research and Development, Jazz Pharmaceuticals, Kura Oncology, Medevir, Merck Sharp & Dohme, Myeloid Therapeutics, Nanjing Sanhome Pharmaceutical, Onyx Pharmaceuticals, Pfizer, Portola Pharmaceuticals, Rafael Pharmaceuticals, Rhizen Pharmaceuticals, Seagen, Secura Bio, Shandong New Time Pharmaceutical, Shanghai Yingli Pharmaceutical, Solasia Pharma, Soligenix, Trillium Therapeutics, VidacPharma, ViGenCell, Yake Biotechnology, and many others.
T-Cell Lymphoma Emerging and Marketed Drugs Covered in the Report Include:
-
SP-02: Solasia Pharma
-
CC-486: Celgene
-
IMC-001: ImmuneOncia Therapeutics
-
Geptanolimab: Genor Biopharma
-
Daratumumab: Janssen Research and Development
-
AT-104: Applied Therapeutics
-
AUTO-5: Autolus
-
IPH4102: Innate Pharma
-
AFM-13: Affimed Therapeutics
-
MT-101: Myeloid Therapeutics
-
CTX130: CRISPR Therapeutics
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. T-Cell Lymphoma Current Treatment Patterns
4. T-Cell Lymphoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. T-Cell Lymphoma Late Stage Products (Phase-III)
7. T-Cell Lymphoma Mid-Stage Products (Phase-II)
8. T-Cell Lymphoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. T-Cell Lymphoma Discontinued Products
13. T-Cell Lymphoma Product Profiles
14. Key Companies in the T-Cell Lymphoma Market
15. Key Products in the T-Cell Lymphoma Therapeutics Segment
16. Dormant and Discontinued Products
17. T-Cell Lymphoma Unmet Needs
18. T-Cell Lymphoma Future Perspectives
19. T-Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/